Notes
The study was funded by AstraZeneca Greece.
Estimated as twice the Gross Domestic Product per capita of that country (calculated using 2015 International Monetary Fund values).
Reference
Tzanetakos C, et al. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical Drug Investigation : 25 May 2016. Available from: URL: http://dx.doi.org/10.1007/s40261-016-0410-2
Rights and permissions
About this article
Cite this article
Adjunctive dapagliflozin for T2DM cost effective in Greece. PharmacoEcon Outcomes News 755, 10 (2016). https://doi.org/10.1007/s40274-016-3117-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3117-y